Morrisville, NC, USA – Worldwide Clinical Trials, Inc., (Worldwide) an award-winning, full-service, midsize, global contract research organization (CRO), announced today that Mike Mencer has joined the company as the EVP and General Manager of Worldwide’s Early Phase Services, focusing on the Bioanalysis Lab in Austin, Texas, and the Clinical Pharmacology Unit (CPU) clinic in San Antonio, Texas.
According to the Pharma Intelligence Pharma R&D Annual Review 2019, the number of drugs in Phase I has increased by 7.2%. Mencer brings 28 years of experience in the pharmaceutical industry to the award-winning Worldwide Phase I team, which is known for easing the burden of budget pressures, tight timelines and the changing regulatory environment for Top 100 biopharma companies, specifically in bioanalytical and CPU services. Mencer and the Worldwide team will continue to leverage an agile and responsive strategy with experience in study design and operations to ensure maximum trial value and seamless linkage with later-stage studies. It is Worldwide’s top priority to provide a sophisticated earlier-phase development program coupled with timely results to facilitate easy decision-making for sponsors throughout the entire clinical development process.
“The biopharma industry is seeking a specialized and personal CRO in their Phase I providers that can provide the expertise they need to develop their molecule further. Mike is the perfect addition to our team to make it happen. Mike’s passion for optimization and operational excellence is well suited to our Early Phase team. We are beyond thrilled to have him on board to move our Phase I team forward,” said Peter Benton, president and COO, Worldwide Clinical Trials.
Mencer enlists with Worldwide following his position as executive director of BD operations at Advanced Enrollment Solutions. In this role, he led the transformation of the inside sales and sales operations teams. He was also the managing director of DMM Triangle Services, LLC, a consulting firm engaged in assisting small and start-up companies. Prior to these positions, Mencer was the VP of Pharmaceutical Development Operations for Patheon N.V., a leading global pharmaceutical contract development and manufacturing organization that is now part of Thermo Fisher Scientific (NYSE: TMO).
“I’m excited to join this uncommon team. I truly appreciate Worldwide’s commitment to excellence and pioneering spirit that makes them a leader in the midsize CRO space,” said Mencer.
Mencer earned his Bachelor of Science in chemical sciences from Xavier University and maintains a PMP certification. Mencer received his operational excellence training from McKinsey & Company.
About Worldwide Clinical Trials:
Worldwide Clinical Trials employs more than 2,000 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval and real-world evidence, we provide world-class, full-service drug development services.
With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO.
For more information, visit http://www.worldwide.com.
Worldwide Clinical Trials